The evolving tariff situation in the US is “hard to predict”, Glenn Saldanha, Glenmark Pharma Chairman and Managing Director, told analysts. However, “given the geopolitical situation, we think Monroe should have a significant benefit, as we go forward. So, it’s only a matter of time,” he said, adding that the last interaction with the US Food and Drug Administration (USFDA) representatives was a couple of months ago. “We send in constant updates to them on the status of our remediation,” he said responding to a query.
Besides Glenmark, other drugmakers with different business models—including Cipla and Piramal Pharma—have recently pointed to the benefits of having facilities in the US as the Trump administration’s “America First” campaign begins to play out.
Meanwhile, Saldanha was optimistic about the next couple of years in the US, with a line-up of launches. While the last quarter of this financial year would see growth on the back of some good launches, he said, there are two major launches in the first half of FY26, including products like fluticasone nasal spray.
Crowded market
In India, he said that the diabetes portfolio is set to see more GLP-1 products, for instance. He said it will be a “crowded market, “ adding that Glenmark was “well positioned” to launch semaglutide in the injectable and oral versions. Semaglutide is the drug for Type II diabetes from Novo Nordisk, and its branded version, Ozempic/Wegovy, is popular internationally for its use in obesity/weight loss. The top management of drugmakers Cipla and Lupin have also indicated that they intend to be in the first wave of companies making this product. Some patents on semaglutide are poised to expire next year.
